Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis : Limiting fibrosis by limiting lysophosphatidic acid synthesis

American Journal of Respiratory Cell and Molecular Biology

Volumn 47, Issue 5, 2012, Pages 563-565

  Tager, Andrew M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOTAXIN; G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPASE; PHOSPHATIDYLCHOLINE; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; COMPETITIVE INHIBITION; DENDRITIC CELL; EDITORIAL; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBROBLAST; FIBROGENESIS; FIBROSING ALVEOLITIS; GENE DELETION; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; INTERSTITIAL PNEUMONIA; LUNG LAVAGE; MACROPHAGE; MELANOMA CELL; NONHUMAN; PATHOGENESIS; PHOSPHOLIPID SYNTHESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; TISSUE INJURY;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LYSOPHOSPHOLIPIDS; MOLECULAR TARGETED THERAPY; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 84868331821     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0235ED     Document Type: Editorial

References (17)

1. Tager AM, Lacamera P, Shea BS, Campanella GS, Selman M, Zhao Z, Polosukhin V, Wain J, Karimi-Shah BA, Kim ND, et al. The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008;14:45-54.
2. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, Prodanovich PC, Fagan P, Baccei CS, Santini AM, Hutchinson JH, et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol 2010;160: 1699-1713.
3. Castelino FV, Seiders J, Bain G, Brooks SF, King C, Swaney JS, Lorrain DS, Chun J, Luster AD, Tager AM. Genetic deletion or pharmacologic antagonism of LPA1 ameliorates dermal fibrosis in a scleroderma mouse model. Arthritis Rheum 2011;63:1405-1415.
4. Pradere JP, Klein J, Gres S, Guigne C, Neau E, Valet P, Calise D, Chun J, Bascands JL, Saulnier-Blache JS, et al. LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 2007;18:3110-3118.
5. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Broadhead AR, Bain G, Santini AM, Darlington J, King CD, Baccei CS, et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther 2010;336:693-700.
6. Oikonomou N, Mouratis MA, Tzouvelekis A, Kaffe E, Valavanis C, Vilaras G, Karameris A, Prestwich GD, Bouros D, Aidinis V. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 2012;47:566-574.
7. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010;50:157-186.
8. Funke M, Xhao Z, Xu Y, Chun J, Tager AM. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis following lung injury. Am J Respir Cell Mol Biol 2012;46:355-364.
9. Aoki J.Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 2004;15:477-489.
10. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, Pettit TR, Wakelam MJO, Saulnier-Blache JS, Mummery CL, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006;26: 5015-5022.
11. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006;281:25822-25830.
12. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992;267: 2524-2529.
13. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002;158:227-233.
14. Jiang G, Madan D, Prestwich GD. Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin. Bioorg Med Chem Lett 2011; 21:5098-5101.
15. Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, McAnulty RJ, Sheppard D, Jenkins G. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 2009;174: 1264-1279.
16. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96: 319-328.
17. Emo J, Meednu N, Chapman TJ, Rezaee F, Balys M, Randall T, Rangasamy T, Georas SN. LPA2 is a negative regulator of both dendritic cell activation and murine models of allergic lung inflammation. J Immunol 2012;188:3784-3790.